Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its holdings in shares of Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) by 1.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 508,900 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,500 shares during the quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Valeant Pharmaceuticals were worth $15,572,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of VRX. Bellevue Group AG raised its stake in shares of Valeant Pharmaceuticals by 30.0% in the second quarter. Bellevue Group AG now owns 130,000 shares of the specialty pharmaceutical company’s stock valued at $3,021,000 after buying an additional 30,000 shares during the period. State of Wisconsin Investment Board raised its stake in shares of Valeant Pharmaceuticals by 6.1% in the second quarter. State of Wisconsin Investment Board now owns 279,956 shares of the specialty pharmaceutical company’s stock valued at $6,512,000 after buying an additional 16,100 shares during the period. Bank of Montreal Can bought a new stake in shares of Valeant Pharmaceuticals in the second quarter valued at $76,236,000. Guggenheim Capital LLC raised its stake in shares of Valeant Pharmaceuticals by 49.6% in the first quarter. Guggenheim Capital LLC now owns 27,511 shares of the specialty pharmaceutical company’s stock valued at $438,000 after buying an additional 9,127 shares during the period. Finally, Moody Lynn & Lieberson LLC bought a new stake in shares of Valeant Pharmaceuticals in the second quarter valued at $2,760,000. Institutional investors and hedge funds own 46.95% of the company’s stock.

Several analysts have issued reports on the company. Deutsche Bank restated a “buy” rating on shares of Valeant Pharmaceuticals in a research note on Friday, June 29th. Mizuho restated a “buy” rating and issued a $31.00 target price on shares of Valeant Pharmaceuticals in a research note on Friday, June 29th. TD Securities lowered Valeant Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 target price on the stock. in a research note on Friday, June 22nd. HC Wainwright restated a “hold” rating and issued a $20.00 target price on shares of Valeant Pharmaceuticals in a research note on Wednesday, June 20th. Finally, Barclays upgraded Valeant Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $20.00 to $34.00 in a research note on Wednesday, June 6th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.51.

Shares of NYSE VRX opened at $23.40 on Friday. The firm has a market capitalization of $8.16 billion, a PE ratio of 6.11, a P/E/G ratio of 0.35 and a beta of -0.38. Valeant Pharmaceuticals has a fifty-two week low of $10.94 and a fifty-two week high of $27.79. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92.

Valeant Pharmaceuticals Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Featured Story: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.